List of Excipients in Branded Drug ALEVE PM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare LLC	ALEVE PM	diphenhydramine hydrochloride and naproxen sodium	0280-1200	ALUMINUM OXIDE
Bayer HealthCare LLC	ALEVE PM	diphenhydramine hydrochloride and naproxen sodium	0280-1200	CARNAUBA WAX
Bayer HealthCare LLC	ALEVE PM	diphenhydramine hydrochloride and naproxen sodium	0280-1200	CELLULOSE, MICROCRYSTALLINE
Bayer HealthCare LLC	ALEVE PM	diphenhydramine hydrochloride and naproxen sodium	0280-1200	FD&C BLUE NO. 2

ALEVE PM Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Aleve PM combines naproxen sodium, a nonsteroidal anti-inflammatory drug, with diphenhydramine citrate, an antihistamine used as a nighttime sleep aid. Its commercial opportunity is primarily in OTC private-label substitution, improved swallowability, faster dissolution, age-restricted combination products, and differentiated dosage forms. The core active-ingredient combination is mature, so excipient selection and product experience are more commercially relevant than exclusivity.

What is Aleve PM and which excipients does it contain?

Aleve PM is an OTC nighttime pain-relief product containing naproxen sodium and diphenhydramine citrate. The labeled dose is two caplets before bedtime, providing 440 mg of naproxen sodium and 50 mg of diphenhydramine hydrochloride equivalent per dose. The product is intended for adults and children age 12 years and older. [1]

Product attribute	Aleve PM
Active ingredients	Naproxen sodium; diphenhydramine citrate
Labeled strength per caplet	Naproxen sodium 220 mg; diphenhydramine citrate equivalent to diphenhydramine HCl 25 mg
Adult dose	Two caplets at bedtime
Therapeutic positioning	Nighttime pain relief and sleep aid
Regulatory category	OTC combination drug
Reference brand	Aleve PM
Primary manufacturer/marketer	Haleon, following the consumer-health transaction involving GSK
Dosage form	Oral caplet
Minimum labeled age	12 years
Key safety constraints	NSAID gastrointestinal and cardiovascular warnings; diphenhydramine sedation and anticholinergic effects

The Aleve PM label identifies inactive ingredients that support tablet manufacture, coating, appearance, lubrication, and mechanical strength. Public labeling for the product identifies excipients including microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, talc, titanium dioxide, and color additives. Exact composition can vary by manufacturing site, market, and packaging presentation, so regulatory comparison should use the current package insert and product-specific FDA listing. [1]

What does each excipient do?

Excipient class	Likely function in Aleve PM
Microcrystalline cellulose	Diluent, compression aid, and tablet-bulk provider
Povidone	Binder that improves granulation and tablet integrity
Sodium lauryl sulfate	Wetting agent that supports dissolution of hydrophobic components
Magnesium stearate	Lubricant for compression and ejection
Talc	Anti-adherent and processing aid
Titanium dioxide	Opacifier and coating pigment
Color additives	Product identification and brand recognition

The formulation challenge is driven by the combination of two active ingredients with different physicochemical and pharmacologic profiles. Naproxen sodium is a relatively high-dose analgesic active, while diphenhydramine is used at a lower dose but has strong taste, sedation, and anticholinergic considerations. The tablet must deliver adequate mechanical strength without creating a slow-dissolving matrix.

How should an excipient strategy be designed for Aleve PM?

The highest-value excipient strategy is a risk-based approach focused on dissolution, manufacturability, swallowability, and consumer tolerability.

Improve dissolution without increasing dose size

Naproxen sodium has better aqueous solubility than naproxen, but the overall product still requires reliable disintegration and dissolution after compression and coating. Excessive lubricant levels, prolonged blending with magnesium stearate, or overly dense compression can slow release.

A reformulated product could use:

• A superdisintegrant such as crospovidone, croscarmellose sodium, or sodium starch glycolate.
• A controlled level of surfactant to improve wetting.
• A directly compressible diluent system that reduces tablet density.
• Granulation conditions that preserve pore structure.
• A lower-hydrophobicity coating system.

Any excipient change would require comparative dissolution testing and, depending on the regulatory pathway and change magnitude, an FDA post-approval change assessment.

Reduce caplet size and improve swallowability

The labeled two-caplet bedtime dose creates a clear consumer burden. Smaller units, a bilayer tablet, or a liquid-filled softgel could improve adherence. Compression optimization should focus on reducing tablet volume while maintaining friability, hardness, coating integrity, and dissolution.

A high-load formulation can use co-processed excipients to improve flow and compressibility. Microcrystalline cellulose remains useful, but excessive use can increase tablet mass. Mannitol, dibasic calcium phosphate, silicified microcrystalline cellulose, or co-processed cellulose systems may provide alternative density and mouthfeel profiles.

The commercial constraint is that reducing size cannot compromise dose uniformity or dissolution. Naproxen sodium occupies most of the active mass, so the practical opportunity is optimization rather than dramatic size reduction.

Manage diphenhydramine taste and mouthfeel

Diphenhydramine products can have a bitter or medicinal taste. Taste masking is more important in chewable, orally disintegrating, liquid, and gummy presentations than in conventional swallowed caplets.

Potential technologies include:

• Polymer coating of diphenhydramine particles.
• Ion-exchange resin complexes.
• Lipid or wax matrices.
• Cyclodextrin complexes.
• Flavor systems with sweeteners and cooling agents.
• Film coating that limits immediate oral exposure.

A taste-masked product would be most commercially relevant if the dosage form changes from a conventional caplet to a chewable or fast-dissolving product. For a standard swallowed caplet, taste masking offers less value than size reduction and faster disintegration.

Avoid excipients that add unnecessary safety or labeling friction

Commercial formulation programs should screen for:

• Color additives that trigger consumer sensitivities.
• High sodium contribution, particularly because naproxen sodium already contributes sodium.
• Lactose or other allergens if a broad private-label platform is intended.
• Sugars in liquid or chewable products.
• Polyethylene glycol or gelatin constraints in softgels.
• Animal-derived materials where vegetarian or religious-market positioning matters.
• Excipient impurities, including elemental impurities and residual solvents.

Excipient selection should align with FDA inactive-ingredient precedents and the Inactive Ingredient Database. [2]

What formulations are protected or commercially differentiated?

Aleve PM's principal commercial differentiation is the combination of naproxen sodium and diphenhydramine in a nighttime oral product. The strongest practical opportunities are dosage-form and user-experience improvements rather than ownership of basic excipients.

Conventional caplet

A conventional caplet has the lowest development risk and the clearest path for private-label substitution. The main value drivers are:

• Lower tablet weight.
• Faster disintegration.
• Stable dissolution across shelf life.
• Robust coating.
• Low manufacturing cost.
• Comparable appearance and packaging.

Softgel

A softgel could improve swallowability and perceived premium quality. It also permits liquid or semisolid fills that may improve wetting and dissolution. The disadvantages are higher manufacturing cost, gelatin or non-gelatin shell constraints, greater moisture sensitivity, and formulation compatibility issues.

A softgel would not automatically avoid the reference product's competitive position. It would create a differentiated dosage form, but FDA requirements for OTC labeling, active equivalence, stability, and manufacturing controls would still apply.

Liquid or chewable product

These formats could target consumers who have difficulty swallowing caplets. Diphenhydramine taste masking would become a major development requirement. Naproxen sodium's relatively high dose makes a liquid product bulky and potentially less convenient. A chewable product also creates exposure to dental and palatability concerns.

Extended-release or staged-release product

A staged-release product could theoretically separate analgesic delivery from nighttime diphenhydramine exposure. The clinical and regulatory rationale is more difficult. The current product uses a single bedtime dose, and altering release kinetics could change pain relief, sedation timing, and safety. This concept has higher development and regulatory risk than a rapid-disintegration caplet.

When does Aleve PM lose exclusivity?

Aleve PM is an OTC product based on long-established active ingredients. The relevant commercial barrier is generally monograph compliance, manufacturing capability, trademarks, trade dress, and formulation know-how rather than new chemical entity exclusivity.

Exclusivity or barrier	Assessment
New chemical entity exclusivity	Not applicable to naproxen sodium or diphenhydramine
Prescription-style FDA approval exclusivity	Not the principal barrier for an OTC monograph product
OTC monograph protection	Applicable regulatory framework for compliant products
Orange Book-listed patents	Product-specific verification is required; OTC monograph status is more relevant than an NDA patent estate
Trademark protection	Aleve and Aleve PM branding
Trade dress	Packaging, color, shape, and presentation may be protectable
Formulation know-how	Manufacturing process, coating, dissolution control, and scale-up
Market exclusivity	Brand recognition, distribution, retailer relationships, and advertising

The FDA's OTC Monograph Drug User Fee Program and monograph system provide the regulatory framework for nonprescription products. Products that comply with applicable monograph conditions generally do not depend on a patent-based exclusivity period comparable to a newly approved prescription drug. [3]

What is the Orange Book status of Aleve PM?

Aleve PM should not be analyzed as a conventional Orange Book patent-blocked prescription product. The Orange Book primarily lists approved drug products approved under new drug applications and abbreviated new drug applications. OTC monograph products generally compete through compliance with the applicable monograph and other FDA requirements rather than through an ANDA Paragraph IV challenge to a branded NDA.

A company considering an Aleve PM equivalent should review:

1. The current FDA Drug Facts labeling.
2. The applicable OTC monograph provisions for internal analgesic, antipyretic, and sleep-aid ingredients.
3. FDA establishment and product-listing data.
4. The inactive-ingredient database.
5. Brand, trademark, and trade-dress constraints.
6. Any current litigation involving Aleve PM or related naproxen/diphenhydramine products.

No Paragraph IV pathway should be assumed solely because the product has a branded reference product. The regulatory route depends on the product's legal status, formulation, labeling, and proposed claims.

Which companies are challenging or competing with Aleve PM?

Competition exists across three categories:

Competitive category	Examples
Direct combination products	Private-label naproxen sodium/diphenhydramine nighttime products
Same-ingredient substitutes	Generic or store-brand naproxen sodium and diphenhydramine products used together
Therapeutic substitutes	Acetaminophen/diphenhydramine products, ibuprofen nighttime products, and non-drug sleep products

The closest direct competitors are likely retailer-owned or generic nighttime analgesic products. The principal business advantage for those products is lower price. The principal advantage for Aleve PM is brand awareness and the consumer association between Aleve and longer-lasting pain relief.

A substitute using acetaminophen and diphenhydramine may have a different safety and positioning profile. An ibuprofen/diphenhydramine product competes more directly on NSAID nighttime pain relief but does not replicate naproxen's dosing interval or consumer perception.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have several routes into the Aleve PM category.

Direct-compression platforms

A co-processed excipient that improves flow, compressibility, and tablet strength could reduce manufacturing costs or enable a smaller caplet. The strongest value proposition is measurable improvement in tablet weight, hardness, friability, and dissolution at commercial scale.

Fast-disintegrating systems

A superdisintegrant or porous carrier system could support a fast-dissolving version. The supplier would need comparative dissolution data in the presence of naproxen sodium, diphenhydramine citrate, lubricant, and coating components.

Taste-masking systems

Taste masking is commercially relevant for chewable, orally disintegrating, and liquid products. Suppliers with polymer coating, ion-exchange, or lipid-matrix technologies could target a new dosage-form program rather than a direct caplet replacement.

Low-allergen and clean-label platforms

Retailers increasingly use excipient positioning in private-label product specifications. Formulations that avoid artificial colors, lactose, animal-derived gelatin, and selected preservatives can support premium or retailer-specific lines. Claims must remain consistent with FDA labeling and substantiation requirements.

Sustainable coatings and packaging

Film coatings with lower solvent use, reduced titanium dioxide dependence, or improved recycling compatibility could support retailer procurement objectives. Packaging changes may produce a faster commercial return than a new dosage form because they require less clinical and formulation redevelopment.

How strong is the Aleve PM patent estate?

The patent estate should be characterized as commercially manageable rather than presumptively strong. The active ingredients are old, and basic naproxen/diphenhydramine combination concepts are unlikely to provide durable composition-of-matter exclusivity. Potential rights may instead concern:

• Specific dosage-form architecture.
• Release profiles.
• Taste masking.
• Coating systems.
• Manufacturing processes.
• Packaging and dispensing systems.
• Brand and trade dress.

Patent diligence should search U.S. and international records under Haleon, GSK, Bayer, and relevant legacy entities, then separate expired patents from live claims. Freedom-to-operate work should cover formulation patents, continuation applications, design patents, trademarks, and retailer-specific private-label agreements.

What generic launch risks exist?

A competing Aleve PM product faces five material risks:

1. The product may not fit cleanly within the applicable OTC monograph.
2. Dissolution may fail after scale-up or stability testing.
3. Diphenhydramine labeling may create sedation-related compliance issues.
4. Trademark or trade-dress similarity may trigger brand-enforcement action.
5. Retailers may demand a lower cost than the formulation can support.

The lowest-risk launch is a conventional caplet with a compliant label and a differentiated appearance. A premium softgel or taste-masked product offers greater pricing potential but requires more formulation, manufacturing, and regulatory work.

Key Takeaways

• Aleve PM contains naproxen sodium and diphenhydramine citrate in a two-caplet bedtime regimen.
• The commercial formulation opportunity is concentrated in excipient optimization, not new active-ingredient protection.
• Microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, talc, titanium dioxide, and colorants support the current caplet platform.
• Fast disintegration, reduced tablet size, and improved swallowability are the most practical formulation priorities.
• Taste masking becomes important for chewable, orally disintegrating, and liquid formats.
• OTC monograph compliance, trademarks, trade dress, manufacturing know-how, and retailer access are more important barriers than Orange Book exclusivity.
• Direct private-label competition is the most credible generic threat.
• Softgels and clean-label caplets offer the clearest premium opportunities, while extended-release concepts carry higher regulatory and clinical risk.

FAQs About Aleve PM Excipient Strategy

Can a generic company use the same excipients as Aleve PM?

Yes. Excipients are generally available for use when the finished product meets applicable FDA requirements. The company must establish safety, quality, stability, manufacturing performance, and label compliance.

Is naproxen sodium more difficult to formulate than naproxen?

Naproxen sodium is generally more water-soluble than naproxen, which can support faster dissolution. Formulation performance still depends on particle properties, compression force, lubricant concentration, coating, and storage conditions.

Could Aleve PM be reformulated as a gummy?

A gummy is technically possible but commercially challenging because the product contains a high naproxen sodium dose and diphenhydramine requires precise dosing and safety labeling. Taste masking, dose uniformity, stability, and child-resistance would be central development issues.

Does diphenhydramine require a special excipient strategy?

Diphenhydramine does not require a unique excipient class, but taste masking, dose uniformity, moisture control, and sedation-related labeling are important. The strategy changes substantially for liquid, chewable, and orally disintegrating products.

Can a private-label product use Aleve PM's appearance?

It can use a functionally similar dosage form only if it avoids confusing similarity with Aleve PM. Trademarks, trade dress, tablet appearance, packaging, and color combinations should be reviewed before commercialization.

References

1. Haleon. (n.d.). Aleve PM drug facts label. U.S. Food and Drug Administration DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs-over-counter-monograph-drugs